| Element List | Current Year | Previous Year | %Change | ||
|---|---|---|---|---|---|
| Sales/Revenue | 842,214 | 739,282 | 13.92 | ||
| Gross Profit (Loss) | 194,768 | 172,290 | 13.05 | ||
| Operational Profit (Loss) | 73,046 | -40,256 | - | ||
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 23,597 | -66,613 | - | ||
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 21,114 | -62,544 | - | ||
| Total Shareholders Equity (after Deducting Minority Equity) | 365,162 | 244,048 | 49.63 | ||
| Profit (Loss) per Share | 1.19 | -3.37 | |||
| All figures are in (Thousands) Saudi Arabia, Riyals | |||||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Thousands) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current year compared to the last year | Arabian International Healthcare Holding Co. (“The Company” or “Tibbiyah”) reported revenue of SAR 842.2 million for FY2025, marking a 13.9% increase from SAR 739.3 million in FY2024. The increase in revenue was primarily driven by improved performance in the Medical Equipment Division (FMS), alongside the stronger contribution from Al-Hammad Medical Services Co. following its acquisition in July 2024. This more than offset the modest decline in the Medical Supplies Division (Premma). |
| The reason of the increase (decrease) in the net profit during the current year compared to the last year is | Arabian International Healthcare Holding Co. (“The Company” or “Tibbiyah”) recorded profit attributable to equity shareholders of SAR 23.6 million in FY2025 (FY2024: net loss of SAR 66.6 million), mainly due to: Revenue: Tibbiyah reported revenue of SAR 842.2 million in FY2025 (FY2024: SAR 739.3 million), representing a 13.9% year-on-year increase. The growth was driven by stronger performance in FMS and a higher contribution from Al-Hammad, partially offset by a modest decline in Premma. Gross profit: Gross profit increased to SAR 194.8 million in FY2025 (FY2024: SAR 172.3 million), reflecting a 13.0% year-on-year increase. Gross margin was 23.1% in FY2025 (FY2024: 23.3%), reflecting broadly stable profitability despite mix and cost movements. Net profit: The year-on-year improvement was primarily driven by higher operating profit and a cleaner earnings profile versus FY2024, including the absence of the SAR 93.7 million goodwill impairment recorded in FY2024, as well as an improvement in credit-loss recognition, with a net reversal of SAR 0.2 million in FY2025 compared to an impairment charge of SAR 17.5 million in FY2024. The improvement was further supported by lower finance charges of SAR 36.1 million versus SAR 40.5 million in FY2024, although higher zakat of SAR 10.2 million (FY2024: SAR 7.8 million) weighed on the bottom line. |
| Statement of the type of external auditor's report | Unmodified opinion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | None |
| Reclassification of Comparison Items | When an operation is classified as a discontinued operation, the comparative statement of profit or loss and OCI is re-presented as if the operation had been discontinued from the start of the comparative year |
| Additional Information | Basic and diluted earnings / (loss) per share are calculated by dividing the profit / (loss) for the year by the weighted average number of outstanding shares during the period. There were no potentially dilutive shares or options in the period, therefore no difference between the basic and the diluted earnings / (loss) per share. |
| Attached Documents | Attached Documents |
